PT  - JOURNAL ARTICLE
AU  - Coltrera, Francesca
ED  - Han, Baohui
TI  - ESTERN
DP  - 2015 Jun 19
TA  - MD Conference Express
PG  - 10--10
VI  - 15
IP  - 8
4099  - http://mdc.sagepub.com/content/15/8/10.short
4100  - http://mdc.sagepub.com/content/15/8/10.full
AB  - In this small phase 2 study, 60% of patients with stage IIIA non–small cell lung cancer with known EGFR mutations (exon 19 or exon 21) were able to proceed to radical resection. The ultimate long-term outcomes associated with this strategy are still undetermined.